[go: up one dir, main page]

MA26933A1 - Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1. - Google Patents

Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.

Info

Publication number
MA26933A1
MA26933A1 MA27006A MA27006A MA26933A1 MA 26933 A1 MA26933 A1 MA 26933A1 MA 27006 A MA27006 A MA 27006A MA 27006 A MA27006 A MA 27006A MA 26933 A1 MA26933 A1 MA 26933A1
Authority
MA
Morocco
Prior art keywords
phenyl
receptor antagonists
pyridine derivatives
neurokinin receptor
neurokinin
Prior art date
Application number
MA27006A
Other languages
English (en)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26933A1 publication Critical patent/MA26933A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA27006A 2000-07-24 2003-01-22 Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1. MA26933A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24

Publications (1)

Publication Number Publication Date
MA26933A1 true MA26933A1 (fr) 2004-12-20

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27006A MA26933A1 (fr) 2000-07-24 2003-01-22 Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.

Country Status (37)

Country Link
US (2) US6576762B2 (fr)
EP (1) EP1305319B1 (fr)
JP (1) JP4118673B2 (fr)
KR (1) KR100527214B1 (fr)
CN (1) CN1192032C (fr)
AR (1) AR029875A1 (fr)
AT (1) ATE322496T1 (fr)
AU (2) AU8200501A (fr)
BR (1) BR0112695A (fr)
CA (1) CA2416874C (fr)
CY (1) CY1106113T1 (fr)
CZ (1) CZ2003528A3 (fr)
DE (1) DE60118569T2 (fr)
DK (1) DK1305319T3 (fr)
EC (1) ECSP034446A (fr)
ES (1) ES2260265T3 (fr)
GT (1) GT200100148A (fr)
HR (1) HRP20030031A2 (fr)
HU (1) HU229231B1 (fr)
IL (2) IL153837A0 (fr)
JO (1) JO2321B1 (fr)
MA (1) MA26933A1 (fr)
MX (1) MXPA03000367A (fr)
MY (1) MY129224A (fr)
NO (1) NO20030353L (fr)
NZ (1) NZ523452A (fr)
PA (1) PA8522801A1 (fr)
PE (1) PE20020258A1 (fr)
PL (1) PL366173A1 (fr)
PT (1) PT1305319E (fr)
RU (1) RU2276139C2 (fr)
SI (1) SI1305319T1 (fr)
TW (1) TWI287003B (fr)
UY (1) UY26851A1 (fr)
WO (1) WO2002008232A1 (fr)
YU (1) YU2803A (fr)
ZA (1) ZA200300219B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US7320994B2 (en) 2002-04-26 2008-01-22 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
JP4895476B2 (ja) 2002-04-26 2012-03-14 イーライ リリー アンド カンパニー タキキニン受容体アンタゴニスト
WO2004032875A2 (fr) * 2002-10-11 2004-04-22 Bristol-Myers Squibb Company Preparation de derives d'heteroaryl-diamine a trois atomes d'azote utiles comme agents pharmaceutiques et procedes de fabrication desdits agents
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
DE602004008631T2 (de) * 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
CA2572645C (fr) 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Procede pour la preparation de derives pyridines carboxamide utilises comme intermediaires dans la synthese d'antagonistes de recepteurs nk-1
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2580694A1 (fr) * 2004-09-23 2006-03-30 Alexander Michalow Methodes permettant de reguler les systemes de neurotransmetteurs en induisant des contre-adaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2006089674A2 (fr) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Comprimés présentant une dispersibilité de substance médicamenteuse améliorée
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
WO2007137954A1 (fr) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Dérivés d'aryl-4-éthynyl-isoxazole
WO2008090114A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
ES2671418T3 (es) 2013-11-08 2018-06-06 Kissei Pharmaceutical Co., Ltd. Derivado de carboximetilpiperidina
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016149324A1 (fr) 2015-03-16 2016-09-22 Vanderbilt University Modulateurs allostériques négatifs du récepteur métabotropique du glutamate de type 2
AU2016377658B2 (en) 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
CA3091944A1 (fr) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Antagonistes nk-1 destines a etre utilises dans le traitement de la douleur oculaire

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
NZ277839A (en) 1993-12-29 1998-01-26 Merck Sharp & Dohme Substituted morpholine derivatives, preparation and pharmaceutical compositions thereof
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1184036A2 (fr) 1998-03-19 2002-03-06 Takeda Chemical Industries, Ltd. Composés hétérocycliques, leur production et leur utilisation comme antagonistes des récepteurs de la tachykinine
RU2238264C2 (ru) * 1999-02-24 2004-10-20 Ф.Хоффманн-Ля Рош Аг Производные бензола или пиридина и фармацевтическая композиция на их основе
JP4068305B2 (ja) * 1999-02-24 2008-03-26 エフ．ホフマン−ラ ロシュ アーゲー ３−フェニルピリジン誘導体、およびそのｎｋ−１受容体拮抗薬としての用途
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
SI1103545T1 (en) * 1999-11-29 2004-02-29 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
NZ523273A (en) * 2000-07-14 2004-08-27 F N-oxides as NK1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives

Also Published As

Publication number Publication date
JO2321B1 (en) 2005-09-12
PA8522801A1 (es) 2002-09-30
TWI287003B (en) 2007-09-21
CN1192032C (zh) 2005-03-09
DE60118569D1 (de) 2006-05-18
YU2803A (sh) 2006-01-16
HUP0301272A2 (hu) 2003-08-28
HRP20030031A2 (en) 2004-02-29
US20030130508A1 (en) 2003-07-10
EP1305319A1 (fr) 2003-05-02
MXPA03000367A (es) 2003-05-27
NZ523452A (en) 2004-07-30
WO2002008232A1 (fr) 2002-01-31
DE60118569T2 (de) 2007-02-15
MY129224A (en) 2007-03-30
PT1305319E (pt) 2006-08-31
BR0112695A (pt) 2003-04-22
US6624176B2 (en) 2003-09-23
UY26851A1 (es) 2002-01-31
HK1058360A1 (en) 2004-05-14
ZA200300219B (en) 2004-04-08
EP1305319B1 (fr) 2006-04-05
JP2004504400A (ja) 2004-02-12
JP4118673B2 (ja) 2008-07-16
DK1305319T3 (da) 2006-08-14
IL153837A0 (en) 2003-07-31
US6576762B2 (en) 2003-06-10
AR029875A1 (es) 2003-07-16
ATE322496T1 (de) 2006-04-15
CA2416874C (fr) 2011-01-18
PL366173A1 (en) 2005-01-24
AU2001282005B2 (en) 2006-10-19
CY1106113T1 (el) 2011-06-08
GT200100148A (es) 2002-05-16
HU229231B1 (en) 2013-09-30
ES2260265T3 (es) 2006-11-01
KR100527214B1 (ko) 2005-11-08
CN1444589A (zh) 2003-09-24
NO20030353D0 (no) 2003-01-23
US20020038030A1 (en) 2002-03-28
KR20030015898A (ko) 2003-02-25
AU8200501A (en) 2002-02-05
ECSP034446A (es) 2003-03-10
CA2416874A1 (fr) 2002-01-31
CZ2003528A3 (cs) 2003-09-17
PE20020258A1 (es) 2002-04-02
SI1305319T1 (sl) 2006-08-31
IL153837A (en) 2008-06-05
NO20030353L (no) 2003-01-23
RU2276139C2 (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
MA26933A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes de recepteur de la neurokinine 1.
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
MA26971A1 (fr) Derives de phenylethenyle ou de phenylethinyle en tant qu'antagonistes de recepteur de glutamate
EP1268449A4 (fr) Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
ATE381565T1 (de) 1,3,8-triaza-spiro 4,5 decan-4-onderivative als neurokininrezeptorantagonisten
DE60134762D1 (de) Metabotropische glutamatrezeptor-antagonisten
FR17C0008I2 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
ATE318259T1 (de) Selektive neurokinin-antagonisten
EP1320366A4 (fr) Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
MA25366A1 (fr) Sulfonamides d'hydroxy-diphenyl cree en tant qu'antagonistes du recepteur il-8.
MA27679A1 (fr) Derives d'acides carboxyliques en tant qu'antagonistes ip
MA27124A1 (fr) 4-(heterocyclysulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl ou pyridylpyrimidines utilisees en tant qu'antagonistes des recepteurs d'endotheline.
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
MA26958A1 (fr) Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
MA27046A1 (fr) Nouveaux derives d'oxazolidinones en tant qu'agents antibacteriens.
NO20013709D0 (no) Nye N-triazolylmetyl-piperazinderivater som neurokininreseptorantagonister
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
MA27094A1 (fr) Derives triazolo-quinoline utiles en tant que ligands recepteurs d'adenosine.
DE60141896D1 (de) N,n'-diarylguanidine als il-8-rezeptor-antagonisten
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
FR2824826B1 (fr) Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
EP1169042A4 (fr) Derives de la dibenzo-azepine en tant qu'antagonistes du recepteur alpha v integrine
ATE310732T1 (de) 7-phenyl-1,4-diazepanderivate als neurokininrezeptorantagonisten